期刊簡介 | |||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名稱![]() | Molecular Cancer LetPub Score 8.5
52 ratings
Rate
Reputation 8.6 Influence 8.3 Speed 8.7 | ||||||||||||||||||||||||
期刊簡稱 | MOL CANCER | ||||||||||||||||||||||||
ISSN | 1476-4598 | ||||||||||||||||||||||||
h-index | 103 | ||||||||||||||||||||||||
CiteScore |
| ||||||||||||||||||||||||
自引率 (2023-2024) | 2.20%自引率趨勢 | ||||||||||||||||||||||||
掲載範囲 |
| ||||||||||||||||||||||||
官方網站 | http://molecular-cancer.biomedcentral.com | ||||||||||||||||||||||||
在線稿件提交 | https://submission.nature.com/new-submission/12943/3 | ||||||||||||||||||||||||
開放訪問 | Yes | ||||||||||||||||||||||||
出版商 | BioMed Central | ||||||||||||||||||||||||
主題領域 | 医学 | ||||||||||||||||||||||||
出版國/地區 | ENGLAND | ||||||||||||||||||||||||
發行頻率 | 月刊 | ||||||||||||||||||||||||
創刊年 | 2002 | ||||||||||||||||||||||||
每年文章數 | 165每年文章數趨勢 | ||||||||||||||||||||||||
黃金OA百分比 | 100.00% | ||||||||||||||||||||||||
OA Related Info![]() | APC: Yes( EUR3990; USD4890; GBP3490; ) APC waiver:Check Notes Other charges: No Keywords: oncology、tumour biology、cancer antigens Useful LinksAims & ScopeAuthor InstructionsEditorial BoardAnonymous peer review | ||||||||||||||||||||||||
Web of Science 四分位 ( 2023-2024) | WOS Quartile: Q1
| ||||||||||||||||||||||||
索引 (SCI or SCIE) | Science Citation Index Expanded | ||||||||||||||||||||||||
鏈接到PubMed Central (PMC) | https://www.ncbi.nlm.nih.gov/nlmcatalog?term=1476-4598%5BISSN%5D | ||||||||||||||||||||||||
平均審稿時間 * | 來自出版商的數據: 來自作者的數據: Average 2 Month(s) | ||||||||||||||||||||||||
競爭力 * | 來自作者的數據: About 50% | ||||||||||||||||||||||||
參考鏈接 |
| ||||||||||||||||||||||||
*所有的審稿過程指標,如接受率和審稿速度,僅限於用戶提交的稿件。因此,這些指標可能無法準確反映期刊的競爭力或速度。 |
|
|
|
首頁 上一頁 4 5 6 7 8 9 10 下一頁 末頁 (頁 | |
[Molecular Cancer] 的評論 | 撰寫評論 |
作者: 大力冰可 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2022-09-24 12:55:41 評論於 Strongly agree. It is true that some articles in Molecular Cancer are not of high quality, but at the very least they do not manipulate Impact Factors like some domestic journals. To put it plainly, it's still some units having double standards – wanting to publish high-scoring articles while avoiding performance evaluations. Just take a look at which units are constantly playing with the so-called blacklist to set the tone. Doesn't Tsinghua University or the Chinese Academy of Sciences still have people publishing in Molecular Cancer? Do those who truly focus on research every day really think about composing blacklists? ![]() ![]() |
作者: Miriam Franklin 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2022-09-24 09:37:48 評論於 Should we hurry up this status as well? ? ![]() ![]() |
作者: Sara Lincoln 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2022-09-23 18:05:42 評論於 Is this so efficient that it does not fit within the scope of the magazine? ![]() ![]() |
作者: 震山今雨 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2022-09-22 20:35:40 評論於 MOLECULAR CANCER is on alert, while those Chinese SCI journals with skyrocketing scores are clearly fake. Why are they not being warned? Definitely they are afraid, after all, they are all full of ****, including academicians who publish in these high scoring but fake Chinese SCI journals ![]() ![]() |
作者: 深渊兰芳 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2022-09-22 18:19:14 評論於 Review speed: 3.0 | Submission hit rate: 50.0 Emphasized research direction: Tumor; Tumor biology Experience sharing: The latest publication by Director Wang Liang from the First Hospital of the Armed Police General Hospital, Malignant clonal evolution drives multiple myeloma cellular ecological diversity and microenvironment reprogramming, looks very good. At least it has broken away from the routine articles full of circRNA in the past. I feel that the editor-in-chief of Molecular Cancer has realized the problem and is starting to turn things around ![]() ![]() |
作者: Edison Springhall 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2022-09-20 21:25:34 評論於 The submission has been 45 days so far, and we have only received one reviewer report ![]() ![]() |
作者: Edison Springhall 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2022-09-20 14:49:01 評論於 I am currently 45 days old ![]() ![]() |
作者: 雾都颖昕 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2022-09-18 21:44:49 評論於 Rejected in 2 days ![]() ![]() |
作者: Miriam Franklin 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2022-09-17 23:54:03 評論於 Is it the same situation for brothers? Is there any news? ![]() ![]() |
作者: Sara Lincoln 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2022-09-17 19:25:53 評論於 Main research focus: Tumors; experience sharing on angiogenesis: submitted for three days, always editor appointed, how long will this state last, what will be the next step ? ![]() ![]() |
作者: Edison Springhall 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2022-09-13 19:04:07 評論於 How is it going? ![]() ![]() |
作者: Lucy Larkin 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2022-09-11 18:03:16 評論於 What you observe is likely an illusion ![]() ![]() |
作者: Edison Springhall 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2022-09-07 17:45:29 評論於 What is your status right now? ![]() ![]() |
作者: 凌霄迎波 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2022-09-07 11:48:08 評論於 What I did is really special and functional. It is particularly evident in animal experiments ![]() ![]() |
作者: 元魁来了 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2022-09-04 11:16:24 評論於 Review speed: 2.0 | Submission hit rate: 50.0 Emphasized research direction: circRNA; tumors; tumor biology Experience sharing: Well, what's the point if your article can't get funded by NSFC even if it's scored 40 or 60? The current situation of the mc is that its reputation within the industry is declining. Although there are some decent articles, the overall approach is conventional and non-coding. Is it true that tumors are only non-coding? In today's situation, the influence of journals lies not only in the Impact Factor but also in the hearts of scientific researchers. To be honest, looking at the journals for grant applications, two mcs are really not as useful as one Cancer Research. Not to mention the old top journals like EMBO, PNAS, and JCI. If you really want to do serious research, it's better to submit to NCS sub-journals or well-known tumor journals ![]() ![]() |
作者: Edison Springhall 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2022-08-29 12:31:52 評論於 Thank you ![]() ![]() |
作者: 四象天晴 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2022-08-27 21:17:34 評論於 Please translate the following passage into English and Japanese ![]() ![]() |
作者: 东海书蝶 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2022-08-26 16:01:00 評論於 Rejected for three days ![]() ![]() |
作者: Edison Springhall 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2022-08-24 21:25:39 評論於 Do you know how many reviewers are needed for the first review? How long does it take for the reviewers to return their feedback after being invited? ![]() ![]() |
作者: Edison Springhall 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2022-08-24 17:06:35 評論於 Hello, are there two reviewers for the first review? How long will it take to receive their feedback? ![]() ![]() |
作者: Edison Springhall 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2022-08-24 16:03:00 評論於 Hello, how many reviewers are there in the first round of review? ![]() ![]() |
作者: Edison Springhall 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2022-08-24 15:40:09 評論於 Hello, a few reviewers after submission ![]() ![]() |
作者: Edison Springhall 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2022-08-24 12:32:04 評論於 Hello, how many reviewers are there after the submission? ![]() ![]() |
作者: Edison Springhall 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2022-08-24 10:51:17 評論於 Hello, may I ask how many reviewers are responsible for reviewing this magazine? ![]() ![]() |
作者: Edison Springhall 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2022-08-24 10:25:39 評論於 Hello, how many reviewers are there for the first review, and how long does it usually take to receive feedback? ![]() ![]() |
首頁 上一頁 4 5 6 7 8 9 10 下一頁 末頁 (頁 |
Contact us